Table 5

Novel agents in MZLs

AgentYearPhasePatient statusNo. of patientsMZLResponse
ORRDuration
Vorinostat10420111RR35922%Median PFS 18.8 mo
Ibrutinib10520131RR56425%NR
Idelalisib1062014*2RR1251547%Median PFS 6.6 mo
Median DOR 18.4 mo
Lenalidomide + Rituximab10720142First line1032789%Median PFS 53.8 mo
  • * Updated at the 56th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA, December 6-9, 2014.